GlassScriptPhysician profile
Jacquelyn E Meldrum
NPI 1639534373
$5,085.23
in general payments reported to CMS, 2019-2025
24 companies · $699 in 2025
The $699 reported for 2025 was more than what 91% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $1,267 · 2023: $1,455 · 2024: $1,193 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Travel and Lodging: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.62 |
| Travel and Lodging | $581.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,533.76 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $1,425.84 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Lilly USA, LLC | $512.33 | 2021-2025 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $295.05 | 2021-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $225.05 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $188.45 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.46 | 2022-2025 | Jardiance |
| Antares Pharma, INC. | $160.92 | 2022-2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $118.02 | 2021-2022 | |
| Mannkind Corporation | $75.02 | 2022-2023 | Afrezza |
| Nevro Corp. | $57.69 | 2023 | Senza |
| Amarin Pharma, INC. | $50.17 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $39.90 | 2022 | |
| Halozyme INC | $37.42 | 2023 | |
| Becton, Dickinson and Company | $34.68 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $23.13 | 2025 | |
| Cequr Corporation | $20.61 | 2024 | Cequr Simplicity |
| Corcept Therapeutics | $18.75 | 2024 | Korlym |
| Verity Pharmaceuticals INC. | $18.75 | 2024 | Tlando |
| Merck Sharp & Dohme LLC | $18.51 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.21 | 2022 | |
| Embecta Corp. | $14.06 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Xeris Pharmaceuticals, INC. | $13.87 | 2024 | Recorlev |
| Abbvie INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Meldrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.